During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Metabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in
disease progression is unclear. We investigated the role of lipid metabolism in prostate …

Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new
perspective in light of the recent advances in research. Although classical NEPC is rarely …

Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …

Objective: Docetaxel (DTX) remains the only effective drug for prolonging survival and
improving quality of life of metastatic castration-resistant prostate cancer (mCRPC) patients …

Despite its good initial response and significant survival benefit in patients with castration-
resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in …

In recent years, natural products have gradually become an important source for new drug
development due to their advantages of multi-components, multi-targets, and good safety …

Mammalian switch/sucrose nonfermentable (mSWI/SNF) ATPase degraders have been
shown to be effective in enhancer-driven cancers by functioning to impede oncogenic …